Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Trevi Therapeutics stock (TRVI)

Buy Trevi Therapeutics stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

Trevi Therapeutics is a biotechnology business based in the US. Trevi Therapeutics shares (TRVI) are listed on the NASDAQ and all prices are listed in US Dollars. Trevi Therapeutics employs 25 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Trevi Therapeutics stock

Top pick for advanced traders

Go to site
Get up to $5,000 cash
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Pro-grade platform and risk analysis tools

Best for beginners

Go to site
Get up to $10,000 cash
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options, with no options contract fees
  • No-cost financial planning and automated investing

Our pick for cash sweep

Go to site
Advanced charts and trading tools
  • Trade stocks, ETFs and equity options without commission and $0 option contract fees
  • Earn up to 8.1% APY on your uninvested cash
  • Get a 1.5% match in cash on transferred assets up to $300 or up to 15 free fractional shares worth between $2 and $2,000

How to buy Trevi Therapeutics stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – TRVI. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy Trevi Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 4 of 4
Name Product Ratings Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
Finder Score: 4.4 / 5: ★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
SoFi Invest®
Finder Score: 4.2 / 5: ★★★★★
SoFi Invest®
Stocks, Options, Mutual funds, ETFs, Alternatives
Get up to $10,000 cash
Commission-free stocks, ETFs and options, with no options per-contract fees. Plus, a no-cost robo-advisor and complimentary access to certified financial planners (CFPs).
Finder Score: 4.3 / 5: ★★★★★
Stocks, Options, ETFs
Up to 8.10%
Choose a 1.5% match or up to 15 free fractional shares
No commission stock, ETF and options trades, with $0 equity options contract fees, low margin rates and advanced trading tools.
Finder Score: 4.2 / 5: ★★★★★
Stocks, Bonds, Options, ETFs, Cryptocurrency, Alternatives, Treasury Bills, High-yield cash account
Get up to $10,000 and transfer fees covered
Build a diversified portfolio of stocks, bonds, options, ETFs, crypto and alternative assets, with a high-yield cash account and options contract rebates.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Trevi Therapeutics stock price (NASDAQ: TRVI)

Use our graph to track the performance of TRVI stocks over time.

Trevi Therapeutics shares at a glance

Information last updated 2024-07-08.
Latest market close$2.80
52-week range$0.97 - $4.00
50-day moving average $2.72
200-day moving average $2.18
Wall St. target price$7.33
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.34

Is it a good time to buy Trevi Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Trevi Therapeutics price performance over time

Historical closes compared with the close of $2.8 from 2024-07-12

1 week (2024-07-05) 8.53%
1 month (2024-06-13) 1.08%
3 months (2024-04-12) -4.11%
6 months (2024-01-12) 97.18%
1 year (2023-07-13) 25.56%
2 years (2022-07-13) -21.79%
3 years (2021-07-13) 38.61%
5 years (2019-07-12) 7.4

Trevi Therapeutics financials

Gross profit TTM $0
Return on assets TTM -24.56%
Return on equity TTM -38.57%
Profit margin 0%
Book value $1.05
Market Capitalization $181.7 million

TTM: trailing 12 months

Trevi Therapeutics share dividends

We're not expecting Trevi Therapeutics to pay a dividend over the next 12 months.

Trevi Therapeutics share price volatility

Over the last 12 months, Trevi Therapeutics's shares have ranged in value from as little as $0.97 up to $4. A popular way to gauge a stock's volatility is its "beta".

TRVI.US volatility(beta: 1.01)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Trevi Therapeutics's is 1.008. This would suggest that Trevi Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Trevi Therapeutics overview

Trevi Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut. .

Frequently asked questions

What percentage of Trevi Therapeutics is owned by insiders or institutions?
Currently 1.286% of Trevi Therapeutics shares are held by insiders and 77.853% by institutions.
How many people work for Trevi Therapeutics?
Latest data suggests 25 work at Trevi Therapeutics.
When does the fiscal year end for Trevi Therapeutics?
Trevi Therapeutics's fiscal year ends in December.
Where is Trevi Therapeutics based?
Trevi Therapeutics's address is: 195 Church Street, New Haven, CT, United States, 06510
What is Trevi Therapeutics's ISIN number?
Trevi Therapeutics's international securities identification number is: US89532M1018
What is Trevi Therapeutics's CUSIP number?
Trevi Therapeutics's Committee on Uniform Securities Identification Procedures number is: 89532M101

More guides on Finder

Ask a Question provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site